Abstract
We report the development of therapy-related early pre-B acute lymphoblastic leukemia in a patient administered a topoisomerase II inhibitor, etoposide, a consolidation therapy agent for acute promyelocytic leukemia. Our case is of interest because of simultaneous relapse of the original leukemia and onset of therapy-related leukemia and relatively rare t(1;11) (p32;q23) translocation with confirmedMLL/AF- 1p fusion. This case suggests that careful monitoring forMLL gene rearrangements is necessary after administration of topoisomerase II inhibitors.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bloomfield CD, Archer KJ, Mrozek K, et al. 11q23 balanced chromosome aberrations in treatment-related myelodysplastic syndromes and acute leukemia: report from an international workshop.Genes Chromosomes Cancer. 2002;33:362–378.
Andersen MK, Christiansen DH, Jensen BA, Ernst P, Hauge G, Pedersen-Bjergaard J. Therapy-related acute lymphoblastic leukaemia withMLL rearrangements following DNA topoisomerase II inhibitors, an increasing problem: report on two new cases and review of the literature since 1992.Br J Haematol. 2001;114: 539–543.
Young BD, Saha V. Chromosome abnormalities in leukaemia: the 11q23 paradigm.Cancer Surv. 1996;28:225–245.
Cimino G, Rapanotti MC, Sprovieri T, Elia L. ALL1 gene alterations in acute leukemia: biological and clinical aspects.Haematologica. 1998;83:350–357.
Martinelli G, Testoni N, Zinzani PL, Biondi A, Cimino G, Tura S. Therapy-related acute leukemia associated with involvement of 11q23 after high grade non-Hodgkin lymphoma.Haematologica. 1998;83:283–284.
Dann EJ, Rowe JM. Biology and therapy of secondary leukaemias.Best Pract Res Clin Haematol. 2001;14:119–137.
Takeyama K, Seto M, Uike N, et al. Therapy-related leukemia and myelodysplastic syndrome: a large-scale Japanese study of clinical and cytogenetic features as well as prognostic factors.Int J Hematol. 2000;71:144–152.
Pui CH, Chessells JM, Camitta B, et al. Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements.Leukemia. 2003;17:700–706.
Sano K. Structure of AF3p21, a new member of mixed lineage leukemia(MLL) fusion partner proteins-implication forMLL-induced leukemogenesis.Leuk Lymphoma. 2001;42:595–602.
Watanabe N, Kobayashi H, Ichiji O, et al. Cryptic insertion and translocation or nondividing leukemic cells disclosed by FISH analysis in infant acute leukemia with discrepant molecular and cytogenetic findings.Leukemia. 2003;17:876–882.
Hayashi Y, Raimondi SC, Behm FG, et al. Two karyotypically independent leukemic clones with the t(8;21) and 11q23 translocation in acute myeloblastic leukemia at relapse.Blood. 1989;73: 1650–1655.
Taki T, Ohnishi H, Shinohara K, et al. AF17q25, a putative septin family gene, fuses the MLL gene in acute myeloid leukemia with t(11;17)(q23;q25).Cancer Res. 1999;59:4261–4265.
Mathew S, Head D, Rubnitz JE, Raimondi SC. Concurrent translocations of MLL and CBFA2 (AML1) genes with new partner breakpoints in a child with secondary myelodysplastic syndrome after treatment of acute lymphoblastic leukemia.Genes Chromosomes Cancer. 2000;28:227–232.
Sawada H, Morimoto H, Wake A, Yamasaki Y, Izumi Y. Therapy- related acute myeloid leukemia with t(10;11)(q23;p15) following successful chemotherapy for acute promyelocytic leukemia with t(15;17)(q22;q21).Int J Hematol. 1999;69:270–271.
Rogaia D, Grignani F, Carbone R, et al. The localization of the HRX/ALL1 protein to specific nuclear subdomains is altered by fusion with its eps15 translocation partner.Cancer Res. 1997;57: 799–802.
Gallagher RE. Retinoic acid resistance in acute promyelocytic leukemia.Leukemia. 2002;16:1940–1958.
Dombret H, Fenaux P, Soignet SL, Tallman MS. Established practice in the treatment of patients with acute promyelocytic leukemia and the introduction of arsenic trioxide as a novel therapy.Semin Hematol. 2002;39:8–13.
Degos L, Wang ZY. All trans retinoic acid in acute promyelocytic leukemia.Oncogene. 2001;20:7140–7145.
Fenaux P, Chomienne C, Degos L. Treatment of acute promyelocytic leukaemia.Best Pract Res Clin Haematol. 2001;14:153–174.
Bernard OA, Mauchauffe M, Mecucci C, Van den Berghe H, Berger R. A novel gene,AF-1p, fused to HRX in t(1;11)(p32;q23), is not related to AF-4, AF-9 nor ENL.Oncogene. 1994;9:1039–1045.
Confalonieri S, Di Fiore PP. The Eps15 homology (EH) domain.FEBS Lett. 2002;513:24–29.
Waterman H, Yarden Y. Molecular mechanisms underlying endocytosis and sorting of ErbB receptor tyrosine kinases.FEBS Lett. 2001;490:142–152.
Santolini E, Salcini AE, Kay BK, Yamabhai M, Di Fiore PP. The EH network.Exp Cell Res. 1999;253:186–209.
Salcini AE, Chen H, Iannolo G, De Camilli P, Di Fiore PP. Epidermal growth factor pathway substrate 15, Eps15.Int J Biochem Cell Biol. 1999;31:805–809.
Marsh M, McMahon HT. The structural era of endocytosis.Science. 1999;285:215–220.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Tsujioka, T., Wada, H., Yamamori, S. et al. MLL/AF-1p Fusion in Therapy-Related Early Pre-B Acute Lymphoblastic Leukemia with t(1;11)(p32;q23) Translocation Developing in the Relapse Phase of Acute Promyelocytic Leukemia. Int J Hematol 78, 439–442 (2003). https://doi.org/10.1007/BF02983817
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF02983817